-
Oct 30, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
European Commission Imposes Heavy Fine on Teva for Misuse of Patent System and Disparaging Rival’s Product*Today, the European Commission (the Commission) fined Teva EUR 462.6 million for abusing its dominant position to delay the market entry of rival medicines for the treatment of relapsing forms of multiple sclerosis (see, attached press release and statement). The Commission established that Teva artificially delayed competition and extended the patent protection of its product Copaxone®...
-
Oct 30, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
European Commission Imposes Heavy Fine on Teva for Misuse of Patent System and Disparaging Rival’s Product*Today, the European Commission (the Commission) fined Teva EUR 462.6 million for abusing its dominant position to delay the market entry of rival medicines for the treatment of relapsing forms of multiple sclerosis (see, attached press release and statement). The Commission established that Teva artificially delayed competition and extended the patent protection of its product Copaxone®...
-
Oct 9, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
Previous article Next article Share on | The Swiss Competition Authority ( Competition Commission or Comco ) indicated today that it terminated its inquiry into patent litigation conducted by Novartis to protect Cosentyx®, a human IgG1 monoclonal antibody indicated for the treatment of several autoimmune diseases, including specific dermatological conditions (see, attached press release in four language versions). Both Comco and the European Commission (the Commission ) had sought to learn...
-
Aug 28, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
The Greek competition authority ( Hellenic Competition Commission or ) announced on 29 August 2024 that it issued a Statement of Objections ( ) against Switzerland-based Novartis and that firm’s Greek subsidiary on account of suspected exclusionary behaviour on the Greek market for the treatment of macular diseases (see, attached press release). The abusive conduct allegedly took place between 2009 and 2017 in two forms: First, Novartis supposedly paid physicians and healthcare inst...
-
Aug 28, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
The Greek competition authority ( Hellenic Competition Commission or ) announced on 29 August 2024 that it issued a Statement of Objections ( ) against Switzerland-based Novartis and that firm’s Greek subsidiary on account of suspected exclusionary behaviour on the Greek market for the treatment of macular diseases (see, attached press release). The abusive conduct allegedly took place between 2009 and 2017 in two forms: First, Novartis supposedly paid physicians and healthcare inst...
-
Aug 28, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
The Greek competition authority ( Hellenic Competition Commission or ) announced on 29 August 2024 that it issued a Statement of Objections ( ) against Switzerland-based Novartis and that firm’s Greek subsidiary on account of suspected exclusionary behaviour on the Greek market for the treatment of macular diseases (see, attached press release). The abusive conduct allegedly took place between 2009 and 2017 in two forms: First, Novartis supposedly paid physicians and healthcare inst...
-
Jul 25, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
Previous article Next article Share on | On 26 July 2024, the European Commission (the Commission ) authorised a EUR 2 billion financing scheme by the Dutch government to support the construction and operation of a nuclear reactor and health centre in Petten, the Netherlands (see, attached Commission press release). The nuclear reactor, called Pallas, will produce medical isotopes as the successor of the existing High Flux Reactor ( HFR ) which has been one of the global leaders for the...
-
Jun 12, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
Previous article Next article Share on | The Luxembourg Competition Authority ( LCA ) announced today that it carried out on-premise inspections in the life sciences sector targeting suppliers of pharmaceutical and related products (see, attached press release).
-
Jun 12, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
Today, the European Commission (the Commission ) publicly announced that it sent a Statement of Objections to Alchem for that firm’s alleged involvement in a cartel in relation to N-Butylbromide Scopolamine/Hyoscine ( SNBB ), the active ingredient of the anti-cramp medicine Buscopan® and its generic versions. Earlier, the Commission had concluded a settlement agreement with the other members of the cartel which agreed to the payment of a total fine of EUR 13.4 million (see, Van Bael & Bellis...
-
Jun 12, 2024 | 
concurrences.com | Van Bael |Michael Clancy |Peter L'Ecluse |Catherine Longeval
Previous article Next article Share on | Today, the European Commission (the Commission ) publicly announced that it sent a Statement of Objections to Alchem for that firm’s alleged involvement in a cartel in relation to N-Butylbromide Scopolamine/Hyoscine ( SNBB ), the active ingredient of the anti-cramp medicine Buscopan® and its generic versions. Earlier, the Commission had concluded a settlement agreement with the other members of the cartel which agreed to the payment of a total fine of...
